atorvastatin has been researched along with Ventricular Fibrillation in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bacova, BS; Benova, T; Knezl, V; Radosinska, J; Tribulova, N; Viczenczova, C | 1 |
| Cheng, W; Hu, H; Li, X; Shi, Y; Wang, Y; Xuan, Y; Xue, M; Yan, S; Yang, N; Yin, J | 1 |
| Bacova, B; Barancik, M; Knezl, V; Kolenova, L; Mitasikova, M; Navarova, J; Radosinska, J; Tribulova, N; Weismann, P | 1 |
| Bernard, D; De Backer, G; De Bacquer, D; De Buyzere, M; De Sutter, J; Jordaens, L; Langlois, M; Matthys, K; Tavernier, R; Van de Veire, NR | 1 |
1 trial(s) available for atorvastatin and Ventricular Fibrillation
| Article | Year |
|---|---|
Coronary risk factors and inflammation in patients with coronary artery disease and internal cardioverter defibrillator implants.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Belgium; Biomarkers; C-Reactive Protein; Coronary Artery Disease; Defibrillators, Implantable; Double-Blind Method; Female; Follow-Up Studies; Glycated Hemoglobin; Greece; Heptanoic Acids; Humans; Inflammation; Inflammation Mediators; Lipids; Male; Middle Aged; Natriuretic Peptide, Brain; Peptide Fragments; Prevalence; Pyrroles; Research Design; Risk Factors; Tachycardia, Ventricular; Treatment Outcome; Ventricular Fibrillation | 2006 |
3 other study(ies) available for atorvastatin and Ventricular Fibrillation
| Article | Year |
|---|---|
Acute anti-fibrillating and defibrillating potential of atorvastatin, melatonin, eicosapentaenoic acid and docosahexaenoic acid demonstrated in isolated heart model.
Topics: Animals; Anti-Arrhythmia Agents; Atorvastatin; Cardiac Pacing, Artificial; Docosahexaenoic Acids; Eicosapentaenoic Acid; Female; Guinea Pigs; Heart Rate; Hypercholesterolemia; Isolated Heart Preparation; Male; Melatonin; Rats; Time Factors; Ventricular Fibrillation | 2015 |
Atorvastatin attenuates sympathetic hyperinnervation together with the augmentation of M2 macrophages in rats postmyocardial infarction.
Topics: Animals; Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Arginase; Atorvastatin; Cells, Cultured; Disease Models, Animal; GAP-43 Protein; Heart; Interleukin-1beta; Macrophage Activation; Macrophages, Peritoneal; Male; Myocardial Infarction; Myocardium; Nerve Growth Factor; Nitric Oxide Synthase Type II; Phenotype; Rats, Wistar; Sympathetic Nervous System; Tachycardia, Ventricular; Tumor Necrosis Factor-alpha; Tyrosine 3-Monooxygenase; Ventricular Fibrillation | 2016 |
Omega-3 fatty acids and atorvastatin suppress ventricular fibrillation inducibility in hypertriglyceridemic rat hearts: implication of intracellular coupling protein, connexin-43.
Topics: Animals; Arrhythmias, Cardiac; Atorvastatin; Blood Pressure; Connexin 43; Fatty Acids, Omega-3; Heart Rate; Heart Ventricles; Heptanoic Acids; Hypertriglyceridemia; Myocardium; Myocytes, Cardiac; Phosphorylation; Pyrroles; Rats; Rats, Wistar; Triglycerides; Up-Regulation; Ventricular Fibrillation | 2010 |